Introduction: Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy are limited. Topotecan is an approved second line chemotherapy for small cell lung cancer (SCLC). NEC is often considered to show a biological behavior similar to SCLC.
Aim(s): To analyze the efficacy of topotecan in pretreated metastastic NEC patients.
Materials and methods: We performed a retrospective analysis of all patients treated with topotecan for metastastic NEC at our center between April 2008 and July 2013 (n=16).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Leonidas Apostolidis
To read results and conclusion, please login ...
Further abstracts you may be interested in